[Clinical characteristics of smoking asthma and efficacy of long-acting muscarinic antagonist in treating patients with smoking asthma] [0.03%]
吸烟哮喘的临床特点以及长期使用抗胆碱能药物治疗吸烟哮喘疗效的研究
X T Huang,L Q Wu,W Dai et al.
X T Huang et al.
Objective: To analyze the clinical characteristics of smoking asthmatic patients and to evaluate the efficacy of long-acting muscarinic antagonist (LAMA) in treating smoking asthmatic patients. Methods: The characteristic analysis study of ...
Randomized Controlled Trial
Zhonghua yi xue za zhi. 2026 May 19;106(18):1835-1842. DOI:10.3760/cma.j.cn112137-20251111-02943 2026
[Clinical practice guideline for integrated PET/MRI in refractory epilepsy(2026 edition)] [0.03%]
难治性癫痫整合型PET/MRI临床实践指南（2026版）
Chinese Society of Medical Imaging Technology;Chinese Society of Radiology;Chinese Society of Nuclear Medicine;Beijing Society of Nuclear Medicine;Beijing Soci
Chinese Society of Medical Imaging Technology;Chinese Society of Radiology;Chinese Society of Nuclear Medicine;Beijing Society of Nuclear Medicine;Beijing Soci
To further standardize the clinical use of integrated PET/MRI brain imaging for refractory epilepsy in China, improve the level of individualized precision diagnosis and treatment, promote standardized management, and provide evidence-based...
[Clinical practice guideline for integrated PET/MRI in brain gliomas(2026 edition)] [0.03%]
脑胶质瘤整合型PET/MRI临床实践指南(2026年版)
Chinese Society of Medical Imaging Technology;Chinese Society of Radiology;Chinese Society of Nuclear Medicine;Beijing Society of Nuclear Medicine;Beijing Soci
Chinese Society of Medical Imaging Technology;Chinese Society of Radiology;Chinese Society of Nuclear Medicine;Beijing Society of Nuclear Medicine;Beijing Soci
To further standardize the clinical application of integrated PET/MRI brain imaging for brain gliomas in China, improve the level of precision diagnosis and management, promote standardized care, and provide evidence-based and consensus rec...
Practice Guideline
Zhonghua yi xue za zhi. 2026 May 19;106(18):1790-1806. DOI:10.3760/cma.j.cn112137-20251222-03388 2026
[Vasomics: an emerging omics discipline for deciphering vascular health and disease] [0.03%]
[血管分子组学——新兴的后基因组学科助力解析血管稳态与疾病]
X L Qi,L Yang,C Y Wang et al.
X L Qi et al.
The vascular system serves as the central architecture of the human circulatory network, whose structural and functional integrity is vital for maintaining homeostasis and is closely associated with the development and progression of major ...
[Progress in targeted therapy for chronic thromboembolic pulmonary hypertension] [0.03%]
慢性肺血栓栓塞性高血压靶向治疗进展
M Zhang,X H Hu,J Wan
M Zhang
Chronic thromboembolic pulmonary hypertension (CTEPH) is a pulmonary vascular disease characterized by organized thrombotic obstruction of the pulmonary arteries and subsequent pulmonary vascular remodeling. The therapeutic strategy has evo...
[Progress in targeted drug therapy for pulmonary hypertension associated with hypoxia] [0.03%]
缺氧性肺动脉高压靶向药物治疗进展
L Liu,Y H Yang
L Liu
Hypoxia-associated pulmonary hypertension (PH) is a severe complication secondary to chronic lung diseases and/or hypoxia, significantly increasing patient mortality risk. Its core pathophysiological mechanisms involve multiple pathways, in...
[Advances in targeted pharmacotherapies for pulmonary hypertension associated with left heart disease] [0.03%]
左心疾病相关肺动脉高压靶向药物治疗进展
H Yao,Y Zhang
H Yao
Pulmonary hypertension associated with left heart disease (PH-LHD) represents the most prevalent form of pulmonary hypertension. The concomitant elevation in pulmonary arterial pressure significantly exacerbates disease morbidity and mortal...
C J Luo,L Wang
C J Luo
Pulmonary arterial hypertension (PAH) is a severe cardiovascular disorder characterized by progressive elevation in pulmonary vascular resistance and sustained increase in right ventricular afterload, which may lead to right heart failure a...
[Innovations in targeted therapies for pulmonary hypertension: advancing from vasodilation to vascular remodeling] [0.03%]
肺动脉高压靶向治疗新策略：从血管舒张到血管重塑
X D Cui,J Y Chen,J Wang
X D Cui
Pulmonary hypertension (PH) is a heterogeneous disease driven by multiple pathological mechanisms. Its core characteristics include pulmonary vascular constriction and pulmonary vascular remodeling. Currently, the clinical treatment of PH p...
[Current status and evolution of targeted therapy for pulmonary arterial hypertension in China] [0.03%]
我国肺动脉高压靶向治疗现状及展望
Q Luo,Z H Liu
Q Luo
Pulmonary hypertension (PH), especially pulmonary arterial hypertension (PAH), is a complex and life-threatening disorder with poor prognosis. Over the past two decades, PAH-targeted therapy in China has evolved through three distinct stage...